You are using an old and unsupported browser. Upgrade to a modern browser for a better experience

Times are shown in your local time zone (GMT )
Mylan

Mylan

Australia
About Mylan
Dymista® 125/50 Nasal Spray is indicated for the symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate. DYMISTA® delivers two times more effective relief of allergic rhinitis symptoms vs. an intranasal corticosteroid spray.*1,2 It has an onset of action from 5 minutes†3,4 and treats the full range of ocular and nasal symptoms of allergic rhinitis, including ocular itch, redness and watering, nasal congestion and itch, rhinorrhoea and sneezing.1-3 *Placebo subtracted rT7SS (reflective total of 7 symptom scores) compared to fluticasone propionate (P = 0.0013) at day 14, post-hoc analysis (n = 610).1,2 †Significant reduction in nasal symptoms (TNSS) from 5 minutes (P < 0.05) and ocular symptoms (TOSS) from 10 minutes (P < 0.05) vs. placebo.3,4 PBS Information: This product is not listed on the PBS. Please review Product Information, available here: https://medicines.org.au/files/gocdymis.pdf , before prescribing. Further information is available on request by calling Mylan Health on 1800 314 527. MYLAN® is a registered trade mark of Mylan Inc. DYMISTA® is a registered trade mark of Meda AB. Copyright© 2020 Mylan N.V. All rights reserved. Mylan Health Pty Ltd, NSW, 2000, Australia. References 1.Meltzer E, et al. Int Arch Allergy Immunol. 2013;161(4):369–77. 2. Hampel FC, et al. Ann Allergy Asthma Immunol. 2010;105(2):168–73. 3. DYMISTA® 125/50 Product Information. 4.Bousquet J, et al. J Allergy Clin Immunol Pract. 2018;6(5):1726–32. For more information please contact: Mylan Camila Reale E: Camila.Reale@mylan.com M: 0413 736 705 W: https://www.mylan.com.au/
Add to Favourites
#ASOHNS ASM 2021
ASOHNS ASM 2021
#ASOHNS ASM 2021
Home
Events